Biomarin biosimilar for mucopolysaccharidosis type VI has received Russian marketing authorization

Pediatric pharmacology
Pediatričeskaâ farmakologiâ

ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)

User

eng | рус

Pediatric pharmacology

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Biomarin biosimilar for mucopolysaccharidosis type VI has received Russian marketing authorization. Pediatric pharmacology. 2025;22(6):773. (In Russ.)

Views PDF (Rus): 7

JATS XML

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Pediatric pharmacology

For citations:

Cookies policy